Excessive mucus production is a common and dangerous feature of asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and acute respiratory infections. It is linked to worse lung function and higher mortality. In COPD, about half of patients show mucus hypersecretion, and their mortality risk is roughly 3.5 times higher than those without it. In asthma, mucus plugs can contribute to fatal airway obstruction. Current treatments—bronchodilators, hypertonic saline, and mucolytics—mainly relieve symptoms and can cause cardiac, visual, urinary, and metabolic side effects. No specific therapy reliably controls mucus overproduction.
A new review, published (DOI: 10.1002/pdi3.70007) in Pediatric Discovery, highlights the epidermal growth factor receptor (EGFR) signaling pathway as a central control point for airway mucus hypersecretion. The review, from researchers at Children's Hospital of Chongqing Medical University in China, synthesizes mechanistic evidence showing how EGFR activation drives goblet cell hyperplasia (GCH) and mucin gene expression. It also evaluates monoclonal antibodies (MABs), tyrosine kinase inhibitors (TKIs), and experimental nanoparticle strategies. The central message is that EGFR-directed therapy could move mucus management beyond symptomatic relief, although safety and airway selectivity remain critical barriers.
The review details how EGFR, a receptor tyrosine kinase also known as ErbB1/HER1, is activated by ligands such as epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), or by oxidative stress in a ligand-independent manner. Activation converges on Ras/Raf/MAPK/ERK signaling and the transcription factor Sp1, promoting mucin 5AC (MUC5AC) and mucin 2 (MUC2) transcription. EGFR activation can also suppress the transcription factor FOXA2 and drive GCH. Sp1 further boosts EGF and TGF-α, creating positive feedback. In preclinical models, an anti-EGFR single-chain antibody fragment displayed on ferritin nanoparticles eased asthma features and reduced GCH and mucus. TKIs including gefitinib, erlotinib, and afatinib reduced MUC5AC and mucus in asthma, COPD, acrolein, and viral-infection models; erlotinib restored claudin 1, a barrier protein whose loss accompanies GCH.
Human evidence remains limited. Inhaled BIBW 2948 was poorly tolerated in COPD, while the downstream inhibitor Bio11006 reached phase IIb. The authors emphasize that efficacy must be balanced against skin, gastrointestinal, hepatic, and pulmonary toxicity. They caution that existing TKIs carry off-target effects and that no successful EGFR-TKI trial has yet been reported in human asthma or COPD. They said future work should prioritize low off-target molecules, optimized delivery devices, and clinical trials that measure both mucus outcomes and systemic safety.
Clinically, EGFR-targeted drugs could complement bronchodilators and mucolytics by reducing the source of excess mucus rather than only clearing it. The most plausible near-term path is inhaled or airway-selective delivery, which may limit systemic toxicity. Patients with severe asthma, COPD with mucus plugs, CF, or virus-driven exacerbations might benefit most, but trials will need to measure mucin burden, lung function, exacerbations, and adverse events. Nanoparticle and antibody-fragment platforms could improve targeting, yet regulators and clinicians will need robust evidence that mucus reduction translates into fewer exacerbations and better survival. The review's implication is clear: EGFR is a promising target, not yet a proven routine treatment. The article is open access and was supported by funding from the Natural Science Foundation of Chongqing and other Chinese research programs. For more information on the journal's publisher, visit http://chuanlink-innovations.com.
